According to Yuyue Medical's announcement, Yuyue Holdings Co., Ltd., a wholly-owned subsidiary of the company, plans to subscribe for Class A1 shares of CFTC Paragon SP and CFTC Paramount SP under the CFTC Summit Fund SPC, with a total subscription amount of no more than HK$100 million. This investment does not need to be submitted to the company's board of directors or shareholders' meeting for review, and does not constitute a related transaction or major asset restructuring. The target fund mainly invests in high-quality PE to IPO projects in the fields of artificial intelligence, semiconductor chips, etc. This investment will not have a significant impact on the company's current financial situation and operating results.

According to Yuyue Medical's announcement, Yuyue Holdings Co., Ltd., a wholly-owned subsidiary of the company, plans to subscribe for Class A1 shares of CFTC Paragon SP and CFTC Paramount SP under the CFTC Summit Fund SPC, with a total subscription amount of no more than HK$100 million. This investment does not need to be submitted to the company's board of directors or shareholders' meeting for review, and does not constitute a related transaction or major asset restructuring. The target fund mainly invests in high-quality PE to IPO projects in the fields of artificial intelligence, semiconductor chips, etc. This investment will not have a significant impact on the company's current financial situation and operating results.